title: Expression of extracellular matrix components versican, chondroitin sulfate, tenascin, and hyaluronan, and their association with disease outcome in node-negative breast cancer.
abstract: OBJECTIVE
  The purpose is to determine whether the levels of expression of extracellular matrix components in peritumoral stroma are predictive of disease outcome for women with node-negative breast cancer.
  
  
  METHODS
  Tumor tissue from 86 patients with node-negative breast cancer was examined by immunohistochemical staining for the expression of versican, chondroitin sulfate (CS), tenascin, and hyaluronan (HA). With the exception of HA, the expression of the extracellular matrix components was measured by video image analysis. Statistical correlation of the immunohistochemical data with clinicopathological characteristics and disease outcome was performed.
  
  
  RESULTS
  All of the extracellular matrix components were present in the peritumoral stroma of the entire study cohort. In contrast, immunoreactivity within the cancer cell was observed in 82% of tumors for HA, 12% for CS, and 4% for tenascin; no immunostaining of cancer cells for versican was observed for any of the tumors. Cox regression and Kaplan-Meier analyses indicated that elevated expression of stromal versican predicted increased risk and rate of relapse in this cohort. Elevated expression of tenascin was predictive of increased risk and rate of death only. Although neither CS nor HA were predictive of disease outcome in this cohort, tumor size was predictive of increased risk and rate of both relapse and survival.
  
  
  CONCLUSIONS
  Elevated expression within peritumoral stromal matrix of versican and tenascin was predictive of relapse-free and overall survival, respectively, in women with node-negative breast cancer.
authors.affiliation: Dame Roma Mitchell Cancer Research Laboratory, Hanson Institute, Adelaide University, Adelaide, South Australia.
authors.forename: Supaporn
authors.initials: S
authors.lastname: Suwiwat
authors.forename: Carmela
authors.initials: C
authors.lastname: Ricciardelli
authors.forename: Raija
authors.initials: R
authors.lastname: Tammi
authors.forename: Markku
authors.initials: M
authors.lastname: Tammi
authors.forename: Paivi
authors.initials: P
authors.lastname: Auvinen
authors.forename: Veli-Matti
authors.initials: VM
authors.lastname: Kosma
authors.forename: Richard G
authors.initials: RG
authors.lastname: LeBaron
authors.forename: Wendy A
authors.initials: WA
authors.lastname: Raymond
authors.forename: Wayne D
authors.initials: WD
authors.lastname: Tilley
authors.forename: David J
authors.initials: DJ
authors.lastname: Horsfall
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000378:metabolism* / Q000628:therapy; D011508:Chondroitin Sulfate Proteoglycans / Q000096:biosynthesis*; D002809:Chondroitin Sulfates / Q000096:biosynthesis*; D015331:Cohort Studies; D018572:Disease-Free Survival; D005109:Extracellular Matrix / Q000378:metabolism*; D005260:Female; D006801:Humans; D006820:Hyaluronic Acid / Q000096:biosynthesis*; D007150:Immunohistochemistry; D037181:Lectins, C-Type; D008198:Lymph Nodes / Q000473:pathology; D008875:Middle Aged; D012044:Regression Analysis; D012306:Risk; D019063:Tenascin / Q000096:biosynthesis*; D013997:Time Factors; D016896:Treatment Outcome; D053675:Versicans
chemical_list: D011508:Chondroitin Sulfate Proteoglycans; D037181:Lectins, C-Type; D019063:Tenascin; C508322:VCAN protein, human; D053675:Versicans; D006820:Hyaluronic Acid; D002809:Chondroitin Sulfates